Topic: Tackling Cisplatin Resistance in Ovarian Cancer
Guest Editor(s)
Special Issue Introduction
Ovarian cancer is the main cause of cancer-related deaths from gynecological cancer. Because diagnosis occurs primarily as advanced disease, the prognosis is poor. In spite of good response to platinum-based therapy, the development of drug resistance represents a major limitation to cure.
Therefore, efforts are needed to define novel strategies to optimize treatment. Research with preclinical models has provided useful results exploited in an attempt to overcome drug resistance. The evidence that the tumor microenvironment can affect response to treatment has stimulated the investigation of mechanisms underlying the role of cell extrinsic factors in drug-resistance regulation. Besides, the molecular characterization of tumors has favored the definition of the molecular features associated with response to treatment and new insights are expected by the investigation on non-coding RNAs. The search for novel biomarkers accurately predicting clinical outcome for patients with advanced epithelial ovarian cancer appears to be a promising field of investigation.
Therefore, efforts are needed to define novel strategies to optimize treatment. Research with preclinical models has provided useful results exploited in an attempt to overcome drug resistance. The evidence that the tumor microenvironment can affect response to treatment has stimulated the investigation of mechanisms underlying the role of cell extrinsic factors in drug-resistance regulation. Besides, the molecular characterization of tumors has favored the definition of the molecular features associated with response to treatment and new insights are expected by the investigation on non-coding RNAs. The search for novel biomarkers accurately predicting clinical outcome for patients with advanced epithelial ovarian cancer appears to be a promising field of investigation.
Keywords
Ovarian cancer, cisplation, platinum, drug resistance, tumor microenvironment, molecular characterization of ovarian tumors, non-coding RNAs, novel biomarkers
Submission Deadline
30 Oct 2020
Submission Information
For Author Instructions, please refer to https://www.oaepublish.com/cdr/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=cdr&SpecialIssueId=431
Submission Deadline: 30 Oct 2020
Contacts: Chloe Yang, Assistant Editor, chloe@cdrjournal.com
Bill Li, Managing Editor, bill@cdrjournal.com
